Guidance on pharmacovigilance procedures in the event of a no-deal Brexit
This guidance summarises our approach to pharmacovigilance in the event of no-deal Brexit.
Documents
Details
This guidance will apply from exit day in line with the Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019.
Updates to this page
Last updated 9 October 2019 + show all updates
-
Major changes to content, including two new sections (9 and 10).
-
Change of text within Stay up to date box.
-
First published.